Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations (Unaudited)

v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Costs and Expenses:    
Research and development $ 85
General and administrative 1,936 1,861
Total costs and expenses 1,936 1,946
Loss from operations (1,936) (1,946)
Change in fair value of warrant liability 294
Other income/(expense), net 15 (4)
Net loss $ (1,921) $ (1,656)
Net loss per share - basic $ (0.30) $ (0.33)
Net loss per share - diluted $ (0.30) $ (0.33)
Weighted average common shares outstanding - basic 6,406,191 5,086,985
Weighted average common shares outstanding - diluted 6,406,191 5,086,985
Net loss attributable to common shareholders $ (1,921) $ (1,656)